(Q27687228)

Stefania Momi

series ordinal

2

1 reference

Emanuela Falcinelli

series ordinal

3

1 reference

language of work or name

English

0 references

publication date

October 2011

1 reference

British Journal of Clinical Pharmacology

published in

1 reference

volume

72

1 reference

issue

4

1 reference

page(s)

634-46

1 reference

Effects of aspirin plus extended-release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second [...]

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195739

Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195739

Dipyridamole for preventing stroke and other vascular events in patients with vascular disease

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195739

Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195739

Effect on platelet function of cilostazol, clopidogrel, and aspirin, each alone or in combination

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195739

RACTS: a prospective randomized antiplatelet trial of cilostazol versus ticlopidine in patients undergoing coronary stenting: long-term clinical and angiographic outcome

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195739

Dipyridamole selectively inhibits inflammatory gene expression in platelet-monocyte aggregates

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195739

Managing PAD with multiple platelet inhibitors: the effect of combination therapy on bleeding time

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195739

Antithrombotic therapy in patients with mechanical and biological prosthetic heart valves

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195739

Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195739

Cyclic GMP-dependent vasodilatory properties of LASSBio 294 in rat aorta

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195739

Fractionation and characterization of a cyclic adenine ribonucleotide formed by tissue particles

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195739

Drug interactions with phosphodiesterase-5 inhibitors used for the treatment of erectile dysfunction or pulmonary hypertension

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195739

Addition of cilostazol to aspirin and a thienopyridine for prevention of restenosis after coronary artery stenting: a meta-analysis

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195739

Population pharmacokinetic analysis of cilostazol in healthy subjects with genetic polymorphisms of CYP3A5, CYP2C19 and ABCB1.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195739

Dipyridamole enhances ischaemia-induced arteriogenesis through an endocrine nitrite/nitric oxide-dependent pathway

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195739

Stroke prevention by cilostazol in patients with atherothrombosis: meta-analysis of placebo-controlled randomized trials

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195739

Potentiation and priming of platelet activation: a potential target for antiplatelet therapy

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195739

Dipyridamole, cerebrovascular disease, and the vasculature

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195739

Update to the AHA/ASA recommendations for the prevention of stroke in patients with stroke and transient ischemic attack

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195739

Translational therapeutics of dipyridamole

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195739

Effects of anagrelide on megakaryopoiesis and platelet production

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195739

Atherosclerotic Vascular Disease Conference: Executive summary: Atherosclerotic Vascular Disease Conference proceeding for healthcare professionals from a special writing group of the American Heart Association

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195739

The pharmacology of cilostazol

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195739

Pharmacology of phosphodiesterase-5 inhibitors.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195739

Antithrombotic therapy in peripheral arterial occlusive disease

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195739

Cyclic nucleotides and phosphodiesterases in platelets

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195739

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195739

Use of sildenafil (Viagra) in patients with cardiovascular disease. Technology and Practice Executive Committee

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195739

Mechanism of action of dipyridamole

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195739

A1- and A2-selective adenosine antagonists: in vivo characterization of cardiovascular effects

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195739

Anagrelide: A New Drug for Treating Thrombocytosis

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195739

Dipyridamole alone or combined with low-dose acetylsalicylic acid inhibits platelet aggregation in human whole blood ex vivo

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195739

Cardiovascular effects of milrinone

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195739

Human blood platelet 3': 5'-cyclic nucleotide phosphodiesterase. Isolation of low-Km and high-Km phosphodiesterase

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195739

Methods for the economic and quality of life supplement to the cilostazol for RESTenosis (CREST) trial

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195739

Pharmacokinetics of multiple-dose oral cilostazol in middle-age and elderly men and women

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195739

Activation of cGMP-stimulated phosphodiesterase by nitroprusside limits cAMP accumulation in human platelets: effects on platelet aggregation

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195739

European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195739

Protection of low density lipoprotein oxidation at chemical and cellular level by the antioxidant drug dipyridamole

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195739

Dipyridamole enhances interleukin-1beta-stimulated nitric oxide production by cultured rat vascular smooth muscle cells

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195739

The influence on platelet aggregation of drugs that affect the accumulation of adenosine 3':5'-cyclic monophosphate in platelets

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195739

Effect of a pyrimido-pyrimidine compound on platelet behaviour in vitro and in vivo.

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195739

Effect of cilostazol on platelet aggregation and experimental thrombosis

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195739

The metabolism of a new antithrombotic and vasodilating agent, cilostazol, in rat, dog and man.

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195739

Effect of cilostazol on experimental cerebral infarction in rabbits.

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195739

Platelet resistance to prostacyclin. Enhancement of the antiaggregatory effect of prostacyclin by pentoxifylline.

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195739

Mechanism of the antiplatelet action of dipyridamole in whole blood: modulation of adenosine concentration and activity.

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195739

Purification and characterization of a human platelet cyclic nucleotide phosphodiesterase

19 June 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2011.04034.X

Novel thienylacylhydrazone derivatives inhibit platelet aggregation through cyclic nucleotides modulation and thromboxane A2 synthesis inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2011.04034.X

Phosphodiesterase 2 mediates redox-sensitive endothelial cell proliferation and angiogenesis by thrombin via Rac1 and NADPH oxidase 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2011.04034.X

Phosphodiesterase 4 inhibitor regulates the TRANCE/OPG ratio via COX-2 expression in a manner similar to PTH in osteoblasts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2011.04034.X

Inhibition of platelet aggregation and the release of P-selectin from platelets by cilostazol

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2011.04034.X

Adding cilostazol to dual antiplatelet therapy achieves greater platelet inhibition than high maintenance dose clopidogrel in patients with acute myocardial infarction: Results of the adjunctive cilostazol versus high maintenance dose clopidogrel in

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2011.04034.X

Cilostazol augments the inhibition of platelet aggregation in clopidogrel low-responders

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2011.04034.X

Recovery of platelet function after withdrawal of cilostazol administered orally for a long period

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2011.04034.X

Cilostazol, a cAMP phosphodiesterase inhibitor, attenuates the production of monocyte chemoattractant protein-1 in response to tumor necrosis factor-alpha in vascular endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2011.04034.X

Evaluation of anti-platelet and anti-thrombotic effects of cilostazol with PFA-100® and Multiplate® whole blood aggregometer in vitro, ex vivo and FeCl3-induced thrombosis models in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2011.04034.X

Meta-analysis of results from eight randomized, placebo-controlled trials on the effect of cilostazol on patients with intermittent claudication

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2011.04034.X

Effect of cilostazol on treadmill walking, community-based walking ability, and health-related quality of life in patients with intermittent claudication due to peripheral arterial disease: meta-analysis of six randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2011.04034.X

Cilostazol for prevention of secondary stroke (CSPS 2): an aspirin-controlled, double-blind, randomised non-inferiority trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2011.04034.X

Cilostazol in addition to aspirin and clopidogrel improves long-term outcomes after percutaneous coronary intervention in patients with acute coronary syndromes: a randomized, controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2011.04034.X

Multicenter randomized trial evaluating the efficacy of cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease: results of the CILON-T (influence of CILostazol-based triple antiplatelet therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2011.04034.X

Periprocedural cilostazol treatment and restenosis after carotid artery stenting: the Retrospective Study of In-Stent Restenosis after Carotid Artery Stenting (ReSISteR-CAS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2011.04034.X

Cilostazol reduces restenosis after carotid artery stenting

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2011.04034.X

Dipyridamole enhances NO/cGMP-mediated vasodilator-stimulated phosphoprotein phosphorylation and signaling in human platelets: in vitro and in vivo/ex vivo studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2011.04034.X

Near-field amplification of antithrombotic effects of dipyridamole through vessel wall cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2011.04034.X

Aspirin plus dipyridamole versus aspirin for prevention of vascular events after stroke or TIA: a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2011.04034.X

The effect of Sildenafil on human platelet secretory function is controlled by a complex interplay between phosphodiesterases 2, 3 and 5.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2011.04034.X

Modulation of human platelet aggregation by the phosphodiesterase type 5 inhibitor sildenafil

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2011.04034.X

The effect of sildenafil on human vascular function, platelet activation, and myocardial ischemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2011.04034.X

Phosphodiesterase inhibitors for pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2011.04034.X

Effects of tadalafil on platelets and endothelium in patients with erectile dysfunction and cardiovascular risk factors: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2011.04034.X

PROLONGING PROSTACYCLIN PRODUCTION BY NAFAZATROM OR DIPYRIDAMOLE

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2011.04034.X

COMBINING ANTIPLATELET AGENTS: POTENTIATION BETWEEN ASPIRIN AND DIPYRIDAMOLE

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2011.04034.X

Differential regulation of human platelet responses by cGMP inhibited and stimulated cAMP phosphodiesterases.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195739

Dipyridamole inhibits platelet aggregation in whole blood

27 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195739

Partial isolation and function of the prostacyclin regulating plasma factor

27 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195739

Relationship between vessel wall 13-HODE synthesis and vessel wall thrombogenicity following injury: influence of salicylate and dipyridamole treatment

27 November 2018

1 reference

12 December 2020

Antiaggregatory effect of oral cilostazol and recovery of platelet aggregability in patients with cerebrovascular disease

1 reference

12 December 2020

Caffeine alters A2A adenosine receptors and their function in human platelets

1 reference

12 December 2020

Inhibition of exercise-induced asthma by an orally absorbed mast cell stabilizer (M & B 22,948)

1 reference

12 December 2020

Potentiation of anti-platelet aggregating activity of cilostazol with vascular endothelial cells

1 reference

12 December 2020

Anti-aggregatory effects of physiological concentrations of adenosine in human whole blood as assessed by filtragometry

1 reference

12 December 2020

Synthesis and antiplatelet evaluation of novel aryl-sulfonamide derivatives, from natural safrole

1 reference

12 December 2020

Tissue distribution of phosphodiesterase families and the effects of sildenafil on tissue cyclic nucleotides, platelet function, and the contractile responses of trabeculae carneae and aortic rings in vitro

1 reference

12 December 2020

Accumulation of radiolabelled platelets and fibrin on the carotid artery of rabbits after angioplasty: effects of heparin and dipyridamole

1 reference

12 December 2020

Effects of anagrelide on platelet cAMP levels, cAMP-dependent protein kinase and thrombin-induced Ca++ fluxes

1 reference

12 December 2020

Comparison of the inhibitory effects of cilostazol, acetylsalicylic acid and ticlopidine on platelet functions ex vivo. Randomized, double-blind cross-over study

1 reference

12 December 2020

Interplay between milrinone and adenosine in the inhibition of human platelet response

1 reference

12 December 2020

Increased platelet aggregability in response to shear stress in acute myocardial infarction and its inhibition by combined therapy with aspirin and cilostazol after coronary intervention

1 reference

12 December 2020

Inhibition and reversal of platelet aggregation by methyl xanthines

1 reference

12 December 2020

Effect of milrinone in human platelet shape change, aggregation and thromboxane A2 synthesis: an in vitro study

1 reference

12 December 2020

Dipyridamole inhibits leukotriene B4 synthesis

1 reference

12 December 2020

Comparison of the effects of acetylsalicylic acid, ticlopidine and cilostazol on primary hemostasis using a quantitative bleeding time test apparatus

1 reference

12 December 2020

Dipyridamole inhibits platelet aggregation induced by oxygen-derived free radicals

1 reference

12 December 2020

Aspirin and dipyridamole in the prevention of restenosis after percutaneous transluminal coronary angioplasty

1 reference

12 December 2020

Cilostazol stroke prevention study: A placebo-controlled double-blind trial for secondary prevention of cerebral infarction

1 reference

12 December 2020

Effect of antioxidants on chemiluminescence produced by reactive oxygen species

1 reference

12 December 2020

Effect of dipyridamole alone and in combination with aspirin on whole blood platelet aggregation, PGI2 generation, and red cell deformability ex vivo in man

1 reference

12 December 2020

Effects of selective inhibitors on cyclic nucleotide phosphodiesterases of rabbit aorta

1 reference

12 December 2020

Inhibition of shear stress-induced platelet aggregation by cilostazol, a specific inhibitor of cGMP-inhibited phosphodiesterase, in vitro and ex vivo

1 reference

12 December 2020

Dipyridamole inhibition of adenosine metabolism in human blood

1 reference

12 December 2020

Antiplatelet activity of dipyridamole in non anticoagulated whole blood

1 reference

12 December 2020

Molecular basis of the synergistic inhibition of platelet function by nitrovasodilators and activators of adenylate cyclase: inhibition of cyclic AMP breakdown by cyclic GMP

1 reference

12 December 2020

1 reference

12 December 2020

Effect of cilostazol, a phosphodiesterase III inhibitor, on experimental thrombosis in the porcine carotid artery

1 reference

12 December 2020

Dipyridamole potentiates the anti-aggregating effect of endothelium-derived relaxing factor

1 reference

12 December 2020

Aspirin extrusion from human platelets through multidrug resistance protein-4-mediated transport: evidence of a reduced drug action in patients after coronary artery bypass grafting

1 reference

12 December 2020

Effect of pentoxifylline on platelet aggregation

1 reference

12 December 2020

Adenosine 3',5'-phosphate in biological materials. I. Purification and properties of cyclic 3',5'-nucleotide phosphodiesterase and use of this enzyme to characterize adenosine 3',5'-phosphate in human urine

1 reference

12 December 2020

A cold start for oral glycoprotein IIb/IIIa antagonists

1 reference

12 December 2020

Role of phosphodiesterase type 3A and 3B in regulating platelet and cardiac function using subtype-selective knockout mice

1 reference

12 December 2020

Cilostazol pharmacokinetics after single and multiple oral doses in healthy males and patients with intermittent claudication resulting from peripheral arterial disease

1 reference

12 December 2020

10.1111/J.1365-2125.2011.04034.X

Identifiers

DOI

1 reference

1 reference

1 reference

PubMed publication ID

21649691

1 reference